Australia's most trusted
source of pharma news
Saturday, 18 October 2025
Posted 17 October 2025 AM
New Zealand's Medsafe has recommended the approval of Vertex's next-in-class, triple combo therapy, Alyftrek, for cystic fibrosis.
Otherwise known as the 'Vanza Triple', Alyftrek is a once daily therapy targeting the underlying cause of the disease by improving CFTR function at and below the cell surface.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.